Novo Nordisk
$70.259876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$70.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.08 (+1.56%) As of 2:16 PM EDT today
Why Robinhood?
You can buy or sell Novo Nordisk and other stocks, options, ETFs, and crypto commission-free!
About NVO
Novo-Nordisk A/S, also called Novo Nordisk, is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. Read More The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark. The listed name for NVO is Novo-Nordisk A/S.
Employees
43,258
Headquarters
Bagsværd, Capital Region
Founded
1925
Market Cap
125.86B
Price-Earnings Ratio
26.49
Dividend Yield
1.35
Average Volume
949.72K
High Today
$70.45
Low Today
$69.50
Open Price
$69.61
Volume
1.02M
52 Week High
$70.45
52 Week Low
$49.24
Collections
Analyst Ratings
50%
of 28 ratings
Buy
50%
Hold
36%
Sell
14%
NVO Earnings
$0.00
$0.25
$0.51
$0.76
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Available Oct 30, Pre-Market